MiniMed Group (NASDAQ:MMED) Hits New 52-Week High – Still a Buy?

Posted by Francis Steltz on Aug 14th, 2026

Shares of MiniMed Group Inc (NASDAQ:MMED – Get Free Report) reached a new 52-week high during trading on Wednesday . The stock traded as high as $20.61 and last traded at $20.55, with a volume of 807216 shares changing hands. The stock had previously closed at $19.78.

Analyst Upgrades and Downgrades

MMED has been the subject of a number of analyst reports. Benchmark reissued a “buy” rating on shares of MiniMed Group in a research note on Thursday, June 4th. Piper Sandler restated a “neutral” rating and issued a $16.00 price target on shares of MiniMed Group in a research note on Thursday, June 4th. Bank of America lowered their price target on MiniMed Group from $27.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. UBS Group began coverage on MiniMed Group in a report on Tuesday, July 28th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Weiss Ratings upgraded MiniMed Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, MiniMed Group has a consensus rating of “Moderate Buy” and an average price target of $21.62.

Read Our Latest Stock Report on MMED

MiniMed Group Stock Performance

The company has a market cap of $5.66 billion and a price-to-earnings ratio of -29.62. The firm’s 50-day moving average price is $16.26.

MiniMed Group (NASDAQ:MMED – Get Free Report) last released its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million for the quarter. The business’s revenue for the quarter was up 15.6% on a year-over-year basis. Sell-side analysts predict that MiniMed Group Inc will post 0.66 EPS for the current year.

Institutional Trading of MiniMed Group

Institutional investors have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in MiniMed Group in the 2nd quarter valued at $91,000. The Manufacturers Life Insurance Company acquired a new stake in MiniMed Group during the 2nd quarter worth $185,000. Deutsche Bank AG purchased a new stake in shares of MiniMed Group during the second quarter worth $420,000. Bank of New York Mellon Corp acquired a new stake in shares of MiniMed Group in the second quarter valued at about $1,058,000. Finally, BlackRock Inc. raised its position in shares of MiniMed Group by 7,527.5% in the second quarter. BlackRock Inc. now owns 1,996,489 shares of the company’s stock valued at $29,848,000 after buying an additional 1,970,314 shares during the last quarter.

About MiniMed Group

(Get Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.